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Abstract
Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, 
survival and response to treatment. Conflicting results are available on the association between rs4919510, a SNP in 
mature miR-608 and clinical outcome in CRC. Here, we analyzed the association between rs4919510 and benefit from 
perioperative treatment in a randomised phase II trial of neoadjuvant Capecitabine and Oxaliplatin (CAPOX) followed 
by chemo-radiotherapy, surgery and adjuvant CAPOX ± Cetuximab in high-risk locally advanced rectal cancer (LARC). 
A total of 155/164 (94.5%) patients were assessable. 95 (61.3%) were homozygous for CC, 55 (35.5%) heterozygous (CG) and 
5 (3.2%) homozygous for GG. Median follow-up was 64.9 months. In the CAPOX arm the 5-year progression-free survival 
(PFS) and overall survival (OS) rates were 54.6% and 60.7% for CC and 82.0% and 82.1% for CG/GG, respectively (HR PFS 
0.13, 95% CI: 0.12–0.83, P = 0.02; HR OS 0.38, 95% CI: 0.14–1.01, P = 0.05). In the CAPOX-C arm PFS and OS were 73.2 and 
82.2%, respectively for CC carriers and 64.6 and 73.1% for CG/GG carriers (HR PFS 1.38, 95% CI: 0.61–3.13, P = 0.44; HR 
OS 1.34, 95% CI: 0.52–3.48, P = 0.55). An interaction was found between study treatment and rs4919510 genotype for 
both PFS (P = 0.02) and OS (P = 0.07). This is the first study investigating rs4919510 in LARC. The CC genotype appeared 
to be associated with worse prognosis compared to the CG/GG genotype in patients treated with chemotherapy and 
chemo-radiotherapy alone. Addition of Cetuximab to chemotherapy and chemo-radiotherapy in CC carriers appeared to 
improve clinical outcome.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://crea-
tivecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, 
provided the original work is properly cited.
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Introduction
Management of locally advanced rectal cancer (LARC) is largely 
based on a number of clinical–radiological factors identified on 
baseline staging. However, it is clear that patients with similar 
risk factors at baseline can have different outcomes and may 
require tailored treatment approaches and surveillance strat-
egies (1). Unfortunately, no predictive/prognostic biomarkers 
are currently available in this setting to allow personalised 
approaches based on tumor biological aggressiveness or initial 
response to neoadjuvant treatment.
MicroRNAs are short, non-coding RNA sequences that reg-
ulate gene expression by targeting hundreds of mRNAs (2). 
A number of key cellular processes including proliferation, dif-
ferentiation and response to anticancer treatments are influ-
enced by this regulatory mechanism (3).
Single nucleotide polymorphisms (SNPs) in microRNA genes 
have been increasingly analysed for their functional implica-
tions. A single base pair change in the nucleoside sequence can 
affect microRNA biogenesis, processing, and target site binding. 
Indeed, microRNA-encoding genes are highly conserved and 
the high frequency of SNPs within microRNA genes supports 
the importance of their function (4). Growing evidence supports 
a link between SNPs in microRNA genes and colorectal cancer 
(CRC) risk, prognosis and drug response (5,6).
The mir-608 gene is located on chromosome 10 (10q24.31): 
a G>C substitution (SNP, rs4919510) affecting the mature miR-
608 sequence has been associated with clinical outcome and 
response to treatment in CRC patients. Although there is a gen-
eral consensus about a potential interaction between rs4919510 
and treatment outcome, discordant findings on the associa-
tion between miR-608 genotype and drug response have been 
observed, most likely due to the lack of proper patient selection, 
heterogeneous chemotherapy regimens and different ethnicity 
in these retrospective series (7–10).
Here we report the first study of the role of rs4919510 in a 
prospective randomised phase II trial (EXPERT-C) of neo-adju-
vant Capecitabine and Oxaliplatin (CAPOX) followed by chemo-
radiotherapy (CRT), surgery and adjuvant CAPOX compared with 
the same treatment plus Cetuximab in Magnetic Resonance 
Imaging (MRI)-defined, high-risk LARC (11).
Materials and methods
EXPERT-C trial design
LARC patients were classified as high risk and eligible for the EXPERT-C 
trial based on the presence of at least one of the following factors on 
high-resolution pelvic MRI: (a) predicted circumferential resection margin 
involvement (i.e. tumor within 1 mm of mesorectal fascia), (b) T3 distal 
tumor (i.e. tumor at/below elevators and extending beyond the muscolaris 
propria), (c) T3c (i.e., extramural tumor invasion between 5 and 15 mm) 
or T3d tumor (i.e. extramural tumor invasion ≥15 mm), (d) T4 tumor (i.e. 
tumor penetrating to the surface of the peritoneum or adherent to/invad-
ing other structures/organs), (e) extramural vascular invasion (EMVI). After 
central randomisation (1:1 ratio) patients received neoadjuvant CAPOX 
Abbreviations 
CRC  colorectal cancer 
EMVI extramural vascular invasion
LARC  locally advanced rectal cancer 
OS overall survival
PFS  progression-free survival
SNP  single nucleotide polymorphism
(four cycles) followed by capecitabine-based CRT, surgery and adjuvant 
CAPOX (four cycles) (CAPOX arm) or the same treatment plus weekly 
Cetuximab (CAPOX-C arm).
The study was approved by local ethics committees and institutional 
review boards and written informed consent was obtained from each 
patient before study entry including consent for future research (ISRCTN 
registration: 99828560).
SNP selection, genotyping and molecular analyses
Only patients who had tumor tissue available for genomic analysis were 
eligible for this study. We selected SNPs in microRNA genes and their bind-
ing sites previously associated with response to treatment in CRC (7,12) 
to test for a potential association with response to neoadjuvant chemo-
therapy and Cetuximab. Results on the association between let-7 comple-
mentary site 6 (LCS6 KRAS variant) and outcome in the EXPERT-C trial have 
previously been reported (13).
DNA was extracted from formalin-fixed paraffin-embedded tumor 
tissue (FFPE) from pre-treatment biopsy and/or post-treatment resec-
tion specimens using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, 
Germany) and from peripheral blood mononuclear cells (PBMC) with 
QIAamp DNA Blood Mini Kit on QIAcube (Qiagen) as we previously 
described (14). Samples were genotyped using the Taqman assay (Life 
Technologies, Carlsbad, CA) for rs4919510 in mir-608. Cases, negative 
controls, and duplicate samples were processed in a random order, with 
10% duplicates to test both inter- and intra-plate concordance. All parties 
involved in genotyping were blinded to the clinical data. Both inter- and 
intra-plate duplicates were 100% concordant. Mutational analyses of KRAS 
(exons 2–4), NRAS (exons 2–4), BRAF (codon 600) and TP53 (exons 4–9) were 
performed centrally on genomic DNA as we previously described (15,16).
Statistical analysis
The Chi-square test was used to assess whether the mir-608 genotypes in the 
study population were in Hardy–Weinberg equilibrium. Progression-free sur-
vival (PFS) was defined as the time between randomization and tumor pro-
gression or death. Patients alive and without evidence of tumor progression 
at the time of the analysis were censored at last follow-up. Overall survival 
(OS) was defined as the time between randomization and death (or censored 
at last follow-up for patients who were alive at the time of the analysis). The 
Kaplan-Meier method was used to calculate survival estimates, and compar-
ison of the treatment arms was carried out using a log-rank analysis. Hazard 
ratios and 95% confidence intervals were obtained from Cox regression. An 
interaction term between treatment arm and mir-608 genotype was included 
in the Cox regression to test for a significant interaction. Multivariate Cox 
regression was used to assess whether a significant interaction remained 
significant after addition of prognostic variables. Prognostic variables includ-
ing sex, World Health Organization (WHO) performance status at baseline 
(0 versus ≥1), baseline T stage (T4 versus other), TNM stage (stage II versus 
stage III) baseline mrEMVI, RAS status (wild-type versus mutant) and TP53 
status (wild-type versus mutant) were included in the multivariate models 
using forward selection if P value in univariate analyses was <0.1.
Results
Genotyping of the rs4919510 locus was performed on DNA 
extracted from pre (n  =  113) and post (n  =  122) neo-adjuvant 
treatment FFPE biopsies in 155 out of 164 eligible patients 
enrolled in the EXPERT-C trial: this cohort represents 94.5% and 
is representative of the trial population as we have previously 
shown (15) (tumor blocks were not available in the remaining 
cases). The same analysis was carried out in 105 pre-treatment 
matching peripheral blood samples (64% of the trial population; 
blood was not available in the remaining cases).
Eighty-one cases had both pre and post treatment biopsies: 
in this group the concordance rate between pre and post-chem-
otherapy genotyping was 98.7%. One discordant case showed GC 
genotype in the pretreatment biopsy and GG genotype in the 
resection specimen. In this case it is possible that neoadjuvant 
treatment might have altered the genotype but given that all 
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the survival outcomes were calculated from randomization, 
only the pretreatment genotype was used in our analysis. DNA 
isolated from tumor tissues has been widely used for pharma-
cogenomic studies; the concordance rate between frequencies 
of SNPs in tumors and their matching bloods appears quite high 
with discordance rate lower than 1.5% (17).
In order to rule out any bias due to somatic alterations (such 
as loss of heterozygosity) that might have affected genotyping 
in FFPE versus bloods, we compared bloods and tumor tissues in 
the 101 patients for whom both materials were available and we 
observed 100% concordance. Interestingly the case with discord-
ant findings between pre and post-treatment tumor samples 
showed concordance of results between pre-treatment tumor 
sample and blood, thus supporting our decision to use the pre-
treatment genotype for analysis. Based on this observation we 
performed all our survival analyses on data obtained from FFPE 
material in order to increase the statistical power of the study.
Sixty patients (38.7%) were found to carry the polymorphic 
variant and these were evenly distributed between the two treat-
ment groups (Table 1). The frequency of the miR-608 genotypes 
did not deviate from the Hardy–Weinberg equilibrium (P = 0.379) 
and no significant association was observed between genotype 
and baseline clinical–pathological characteristics or mutations 
in the KRAS, NRAS, BRAF, PIK3CA and TP53 gene. (Table 2).
After a median follow-up of 64.9 months (95% CI: 62.8–67.2), 
no statistically significant differences in PFS [63.5% (95% CI: 53.7–
73.3) versus 72.9% (95% CI: 61.5–84.3) at 5 years; HR 0.67 (95% CI: 
0.37–1.21) P = 0.18] and OS [71.0% (95% CI: 61.8–80.2) versus 77.6% 
(95% CI: 66.8–88.4) at 5 years, HR 0.66 (95% CI: 0.34–1.26), P = 0.208] 
were observed in the overall population between patients 
homozygous for the C allele and those carrying the G allele.
In the CAPOX arm, patients with the CC genotype had worse 
5-year PFS [54.6% (95% CI: 40.5–68.7) versus 82.0% (95% CI: 67.7–
96.3) HR 0.13 (95% CI: 0.12–0.83) P  =  0.019, adjusted P  =  0.010] 
and 5-year OS [60.7% (95% CI: 47.0–74.4) versus 82.1% (95% CI: 
68.0–96.2) HR 0.38 (95% CI: 0.14–1.01), P = 0.053, adjusted P = 0.033 
(adjusted for p53 mutations (15)] compared to patients with the 
variant genotype (Figure  1A and B). These findings are in line 
with the data observed by Pardini (7) and Xing (8), and confirm 
an association between CC genotype and poor outcome in CRC.
Conversely, no survival differences by genotype were observed 
in the group of patients who received Cetuximab in combination 
with chemotherapy and CRT. The 5-year PFS was 73.2% (95% CI: 
60.3–86.1) in patients homozygous for the C allele and 64.6% (95% 
CI: 47.7–81.5) in patients carrying the G allele [HR 1.38 (95% CI: 0.61–
3.13) P = 0.439]. In the same genotype groups, the 5-year OS rates 
were 82.2% (95% CI: 71.0–93.4) and 73.1% (95% CI: 57.0–89.2) [HR 
1.34 (95% CI: 0.52–3.48) P = 0.548], respectively (Figure 1C and D).
When we explored the effect of the addition of Cetuximab 
to chemotherapy and CRT in the CC carriers we noticed an 
improved 5-year PFS [73.2% (95% CI: 60.3–86.1) versus 54.6% (95% 
CI: 40.5–68.7) p: 0.036], and 5-year OS [82.2% (95% CI: 71.0–93.4) 
versus 60.7% (95% CI: 47.0–74.4), p: 0.023] (Figure 2A and B). The 
rate of complete responses in CC carriers was increased in the 
CAPOX-C arm (17.8%) versus the CAPOX arm (12.0) (Table  3), 
however the difference was not statistically significant possibly 
due to the small number of patients in the trial.
Table  1. miR-608 genotype in the entire study population and by 
treatment arm
miR-608 genotype
CAPOX CAPOX-C All patients
N (%) N (%) N (%)
CC 50 (64.1) 45 (58.4) 95 (61.3)
CG 25 (32.1) 30 (39.0) 55 (35.5)
GG 3 (3.8) 2 (2.6) 5 (3.2)
CAPOX, Capecitabine + Oxaliplatin; CAPOX-C, Capecitabine + Oxaliplatin + 
Cetuximab.
Table 2. Baseline patient characteristics by mir-608 genotype and treatment arm
CAPOX (n = 78) CAPOX-C (n = 77)
CC (n = 50) (%) CG/GG (n = 28) (%) CC (n = 45) (%) CG/GG (n = 32) (%)
Gender
 Male 27 (54.0) 17 (60.7) 29 (64.4) 21 (65.6)
 Female 23 (46.0) 11 (39.3) 16 (35.6) 11 (34.4)
Age (years)
Median (range) 66 (28–79) 64 (35–75) 59 (31–75) 60 (35–75)
WHO PS
 0 23 (46.0) 14 (50.0) 25 (55.6) 11 (34.4)
 ≥1 27 (54.0) 14 (50.0) 20 (44.4) 21 (65.6)
MRI high-risk features
 T3c–T3d (≥5 mm) 36 (72.0) 18 (64.3) 23 (51.1) 21 (65.6)
 T4 11 (22.0) 8 (28.6) 14 (31.1) 6 (18.8)
 CRM+/at risk 28 (56.0) 17 (60.7) 26 (57.8) 18 (56.3)
 EMVI positive 37 (74.0) 21 (75.0) 32 (71.1) 24 (75.0)
 Low lying tumor 34 (68.0) 20 (71.4) 31 (68.9) 29 (90.6)
Tumor mutations
 KRAS 21 (42.0) 11 (39.3) 17 (37.8) 17 (53.1)
 NRAS 2 (4.0) 2 (7.1) 2 (4.4) 0
 KRAS/NRAS 23 (46.0) 13 (46.4) 19 (42.2) 17 (53.1)
 BRAF 0 2 (7.1) 0 2 (6.3)
 PI3KCA 6 (12.0) 1 (3.6) 3 (6.7) 0
 TP53 24 (48.0) 11 (39.3) 20 (44.4) 20 (62.5)
CAPOX, Capecitabine + Oxaliplatin; CAPOX-C, Capecitabine + Oxaliplatin + Cetuximab; PS, Performance Status; WHO, World Health Organization.
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In the CG/GG carriers, who appear to have a better prog-
nosis compared to CC carriers, addition of Cetuximab to 
chemotherapy and CRT was not associated with any clinical 
benefit: 5-year PFS in the CAPOX arm was 82.0% (95% CI: 67.7–
96.3) versus 64.6% (95% CI: 47.7–81.5) in the CAPOX-C arm [HR 
2.17 (95% CI: 0.75–6.25), P  =  0.152]; 5-year OS were 82.1% (95% 
CI: 68.0–96.2) and 73.1% (95% CI: 57.0–89.2), respectively [HR 1.48 
(95% CI: 0.48–4.53), P = 0.492] (Supplementary Figure 1, available 
at Carcinogenesis Online). In contrast, combining Cetuximab with 
chemotherapy and CRT appeared to have a detrimental effect 
in carriers of the variant alleles, who were found to have an 
increased risk of distant relapse [Distant Relapse rate for the 
CAPOX-C arm 35.4% (95% CI: 18.5–52.3) versus 15.0% in CAPOX 
(95% CI: 1.5%–28.5%); HR 2.73 (95% CI: 0.87–8.59) P = 0.086] which 
translated into worse Distant Relapse Free Survival [CAPOX 
arm 85.0% (95% CI: 71.5–98.5) versus CAPOX-C 64.6% (95% CI: 
47.7–81.5), HR 2.73 (95% CI: 0.87–8.59) with a trend towards a 
Figure 2. Survival outcomes in patients with the CC genotype according to treatment. Progression-free survival (A) and Overall survival (B). CAPOX, Capecitabine + 
Oxaliplatin; CAPOX-C, Capecitabine + Oxaliplatin + Cetuximab; CI, confidence interval; PFS, progression-free survival; OS, overall survival; HR, hazard ratio. 









N (%) N (%) N (%)
CC 6/50 (12.0) 8/45 (17.8) 0.564 14/95 (14.7)
CG/GG 4/28 (14.3) 4/32 (12.5) 1.00 8/60 (13.3)
P value 0.740 0.751 0.807
CAPOX, Capecitabine + Oxaliplatin; CAPOX-C, Capecitabine + Oxaliplatin + 
Cetuximab.
Figure 1. Survival outcomes according to miR-608 genotype in the study population. Progression-free survival (A) and overall survival (B) in the CAPOX (Capecitabine + 
Oxaliplatin) arm; progression-free survival (C) and overall survival (D) in the CAPOX-C (Capecitabine + Oxaliplatin + Cetuximab) arm. CI, confidence interval; HR, hazard 
ratio; PFS, progression-free survival; OS, overall survival.
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statistically significant interaction for distant tumor recurrence 
between treatment and rs4919510 (P = 0.060; adjusted P = 0.092).
Discussion
In this retrospective analysis of the EXPERT-C trial, we have 
shown that the miR-608 CC genotype is associated with worse 
outcome when compared to the CG/GG genotypes in rectal 
cancer patients treated with neoadjuvant systemic chemo-
therapy followed by CRT, surgery and adjuvant chemotherapy. 
Interestingly, the addition of Cetuximab to this intensified treat-
ment strategy seemed to rescue the poor prognosis of patients 
with the CC genotype. To our knowledge, our study is the first 
to evaluate the prognostic role of rs4919510 in a homogeneous 
cohort of rectal cancer patients. Our patient population was 
represented by a prospectively collected series of LARC patients 
with an extensive molecular characterisation.
Previous case-control studies have explored miR-608 in rela-
tion to survival in CRC patients, with conflicting results. Pardini 
et al. (7) studied a European cohort of CRC patients and confirmed 
the presence of an association between rs4919510 and survival 
only in patients with stage III CRC who received 5-Fluorouracil 
(5-FU) based adjuvant chemotherapy. They observed that carri-
ers of the G allele were at significantly decreased risk of recur-
rence when compared with CC genotype carriers. Similarly, 
Xing et al. (8) found that this SNP was associated with favourable 
outcome in 319 patients who received FOLFOX adjuvant chemo-
therapy, while this association was not evident in 89 patients 
who did not receive chemotherapy.
Contrary to these studies, Lin et  al. (9) reported that the 
rs4919510 SNP was associated with poor outcome in stage III 
CRC receiving 5-FU based adjuvant chemotherapy. Several fac-
tors may account for the discrepancy between Lin’s findings and 
our observations: (i) both the training and the replication set 
in Lin’s study included 10% African-American (and 10% other 
ethnicities) in whom GG genotype was shown to be more fre-
quent; (ii) while our cohort included only rectal cancer, Lin and 
colleagues studied a mixed population of proximal and distal 
colon and rectal cancers with the latter being less than 50%. 
Despite their analysis included adjustment for tumor site, the 
proportion of rectal cancer in the 179 stage III CRC patients is 
not specified.
As Ryan (4) and colleagues pointed out, ethnicity may 
account for important discrepancies in the prediction of CRC 
risk and prognosis among different populations: they found a 
significant association between the variant GG genotype and 
increased risk of death in Caucasian patients. Conversely, in 
African-American patients, there was a trend for the GG geno-
type to be associated with decreased risk of death, although this 
did not reach statistical significance (HR GG versus CC 0.38, 95% 
CI, 0.13–1.13, P = 0.082, adjusted HR GG versus CC 0.36, 95% CI 
0.12–1.07, P = 0.66). Unfortunately the study did not include clini-
cal information related to treatment, making comparison with 
our study challenging.
MicroRNA expression is tissue and organ specific and differ-
ences in microRNA deregulation have been observed in rectal 
compared to colon cancers (18–21). It is likely that the effects 
of rs4919510 on the interaction between miR-608 and its wide 
spectrum of target mRNAs may also differ according to the 
location of the primary tumor, thus possibly explaining some 
divergent results observed among studies which included het-
erogeneous patient populations. Notably, as suggested by Ryan 
and colleagues, two genes involved in the fluoropyrimidine 
metabolism [thymidine kinase and folylpolyglutamate synthase 
(10,22)] have been included in the list of putative targets of miR-
608 and may potentially account for the effects of rs4919510 on 
the modulation of response to fluorouracil when given in com-
bination with other chemotherapy drugs or as a radio-sensitizer 
with radiotherapy.
All patients included in our study received the same treat-
ment with the exception of the addition of Cetuximab for 
those randomised to the investigational arm. This allowed us 
to explore for the first time the potential association between 
rs4919510 and activity of this anti-epidermal growth factor 
(EGFR) monoclonal antibody. Notably, the administration of 
Cetuximab appeared to improve the outcome of patients with 
the CC genotype while no incremental benefit from its use 
was observed in the group of patients with the CG/GG geno-
types. This resulted in a statistically significant interaction for 
survival between Cetuximab treatment and mir-608 genotype. 
These findings suggest that rs4919510 may potentially interfere 
with the mechanism of action of Cetuximab ultimately lead-
ing to an attenuation of its anti-tumor properties. In support of 
this theory, miR-608 has been reported to target the EGFR and 
other genes which were previously shown to mediate resist-
ance to EGFR inhibition such as MET (23). Alteration of binding 
affinities of mir-608 to these targets may explain the absence of 
Cetuximab benefit in carriers of the G allele.
Even though our cohort has been prospectively collected 
and is homogeneous in term of ethnicity and treatment, we 
acknowledge that our study may have some limitations: (i) 
the analysis of rs4919510 was not originally planned when the 
EXPERT-C study was designed and therefore it suffers from all 
the limitations inherent to retrospective biomarker analyses; 
(ii) Given the investigational nature of both treatment arms of 
the EXPERT-C trial, it is not known whether the study findings 
are applicable to a rectal cancer patient population treated with 
standard fluoropyrimidine-based CRT.
In conclusion, we believe that our findings are of interest and 
support the importance of small non-coding RNAs as potential 
determinants of tumor aggressiveness and/or response to treat-
ment in LARC patients prompting further analysis in this set-
ting. An extensive analysis of microRNA expression in patients 
from the same series is ongoing.
Supplementary material
Supplementary Figure  1 can be found at http://carcin.oxford-
journals.org/
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